Compare Charles River Laboratories Intl. Inc (CRL) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs United Airlines Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $284.05 (market cap $13.58B), while United Airlines Holdings Inc trades at $126.3 (market cap $40.61B). The key difference: United Airlines Holdings Inc is far larger — about 3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CRL | UAL | |
|---|---|---|
Market Cap | $13.58B | $40.61B |
Sector | Health | Industrials |
52-Week High | $284.37 | $136.11 |
52-Week Low | $145.57 | $85.21 |
Enterprise Value | $16.41B | $57.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $281.27, near its 52-week high, with a slight 0.26% decline. The stock shows bullish technical signals, including strong moving averages, despite overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $3.02 versus $2.74 expected, and the company raised full-year guidance, reflecting improved biotech demand. However, fundamentals reveal challenges, with a negative net income margin of -5.96% and elevated P/E ratio of 684.85, indicating high valuation relative to profitability.
Outlook: CRL benefits from positive analyst sentiment (72% buy ratings) and institutional accumulation, but risks include profitability pressures, high debt, and reliance on biotech sector health. The consensus price target of $277.29 suggests limited upside, urging caution despite operational improvements.
United Airlines (UAL) trades at $126.35, up 0.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $167.73. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.99 surpassing expectations, and maintains solid profitability with a net income margin of 5.56%. Recent news highlights fleet innovation focus after merger attempts failed, while cash flow trends show improvement into 2026.
UAL presents a favorable investment case with undervalued metrics like a P/E of 11.72 and robust analyst support (66% buy ratings), but faces risks from fuel cost volatility and execution challenges. The stock's upside potential hinges on sustained travel demand and cost management, with net cash flow turning positive in 2026 projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
